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PCommentary
High-Sensitivity C-Reactive Protein in Every Chart?
The Use of Biomarkers in Individual Patients
Ori Ben-Yehuda, MD
San Diego, California
The use of high-sensitivity C-reactive protein (hsCRP) for risk stratification for cardiovascular disease is sup-
ported by epidemiologic evidence but remains controversial. The metabolic milieu in which hsCRP is likely to be
elevated, namely abdominal obesity and insulin resistance, provides a framework for the understanding of the
role of hsCRP as well its limitations. This commentary provides a critical assessment of the data in support of
the use of hsCRP in clinical practice. (J Am Coll Cardiol 2007;49:2139–41) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.007b
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mt has been over a decade since high-sensitivity C-reactive
rotein (hsCRP) was proposed as a risk marker for future
ardiovascular events. The large body of evidence showing
he incremental value of hsCRP when added to traditional
isk factors has also been used to support the hypothesis that
therosclerosis is first and foremost an inflammatory disease.
n this issue of the Journal, Dr. Paul Ridker, one of the
eading researchers in this field, eloquently defends the use
f hsCRP and advocates that a consensus can be reached for
he use of this biomarker, particularly for patients at
ntermediate risk for cardiovascular events (1). Is this a
losed and shut case, or is there still room for controversy
egarding the utility of hsCRP? Should hsCRP be an
ntegral part of cardiovascular risk assessment? The answer
o this question has important implications for the inflam-
atory hypothesis in particular, as well as for the clinical use
f biomarkers in general as prognostic markers.
Critics of the use of hsCRP can cite several studies,
ncluding recent reports from the Framingham Offspring
tudy (2), PROSPER (Prospective Study of Pravastatin in
he Elderly at Risk) (3), and the multiethnic Dallas Heart
tudy (4), in which hsCRP provided only modest or no
ncremental information compared with traditional risk
actors. The Dallas Heart Study is of particular interest
ecause the assessment is of the atherosclerosis burden itself
detected by electron beam computed tomographic calcium
core and magnetic resonance imaging-detected aortic
laque). How can we make sense of this literature, and is
here a biological explanation for these divergent findings?
In the assessment of hsCRP (as with any biomarker) and
ts role in cardiovascular disease, we should first examine the
rom the Department of Medicine, University of California, San Diego Medical
enter, San Diego, California.n
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ccepted March 28, 2007.iological context in which an elevation of this biomarker
ccurs. Proponents of the use of hsCRP emphasize that
laque can be a source of CRP as well as a target for its
athological effects. The main source of CRP in the body,
owever, is the liver (5). And although vascular inflamma-
ion may contribute to an elevation of CRP in the blood, the
ain association is with abdominal obesity and insulin
esistance. Abdominal adipocytes are a rich source of various
nflammatory cytokines, including interleukin-6 (6).
nterleukin-6 in particular is a potent messenger for the liver
o secrete CRP. Indeed, abdominal obesity and insulin
esistance are predictors of an elevated hsCRP, and the
resence of the metabolic syndrome correlates strongly with
n elevated hsCRP level (5,7). Conversely, patients with 0,
, or even 2 risk factors for the metabolic syndrome have low
RP levels (7).
Given the clear association between abdominal obesity,
nsulin resistance, and elevated hsCRP, we should exam-
ne the metabolic milieu in which elevated levels of
sCRP occur. The patient with metabolic syndrome and
nsulin resistance is likely to show a pattern B lipoprotein
rofile, with elevations in highly atherogenic apolipo-
rotein-B– containing particles, such as very-low-density
ipoprotein (VLDL) remnants, intermediate-density li-
oprotein, and chylomicron remnants, as well as an
ncrease in small-dense low-density lipoprotein (LDL)
nd therefore LDL particle number (8). A fairly good
ssessment of the presence of this highly atherogenic
rofile can be obtained by calculating non–high-density
ipoprotein (HDL) cholesterol, a simple measurement
lready available in our patients’ charts. Thus, the risk
ttributed to hsCRP actually may be the result of
levations of non-LDL atherogenic particles rather than
n independent contribution of inflammation. Indeed,
ost of the studies in support of the use of hsCRP did
ot fully control for the presence of the metabolic
s
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resence of a pattern B profile. One exception is the
HS (Women’s Health Study), in which Ridker et al.
7) examined the effect of hsCRP in subjects with and
ithout the metabolic syndrome. Most importantly, in
he absence of the metabolic syndrome, an elevated
sCRP did not significantly predict increased risk, sig-
ificantly detracting from the argument that CRP is an
ndependent and causally implicated mediator. And al-
hough hsCRP 3 mg/dl in subjects with the metabolic
yndrome did predict even added risk, metabolic syn-
rome subjects with hsCRP 3 mg/dl were already at
ncreased risk compared with those without the metabolic
yndrome (relative risk of any cardiovascular event of 2.3
nd 3.1 for coronary events) (7). For the patient with
etabolic syndrome, the presence of an elevated hsCRP
ay further indicate the need for aggressive intervention.
his is one group of patients in whom hsCRP may be
seful as a barometer of the overall inflammatory state,
urther identifying the particularly high-risk patient.
High-sensitivity CRP also has been proposed as a pre-
ictor of clinical response to statin therapy. It has been
laimed that the benefit of statin therapy may be related to
he so-called pleiotropic effects of statins, particularly their
nti-inflammatory and hsCRP-lowering effects. As Ridker
t al. (9) point out, patients in the PROVE-IT–TIMI-22
Pravastatin or Atorvastatin Evaluation and Infection Ther-
py–Thrombolysis In Myocardial Infarction-22) trial who
ad LDL70 mg/dl as well as hsCRP2 mg/dl had lower
vent rates compared with those who did not have both of
hese target goals achieved. This analysis, however, did not
ake into account baseline LDL cholesterol levels or baseline
sCRP levels. Similarly, the finding that patients with
levated hsCRP levels are particularly likely to benefit from
tatin therapy in terms of cardiovascular event reduction is
onfounded by the fact that it is the low-HDL, high-
riglyceride patient (who also is likely to be the metabolic
yndrome insulin-resistant patient and therefore to have a
igh hsCRP) who is the one most likely to benefit from
tatin therapy (10).
Statin therapy has been shown to reduce hsCRP levels.
hat is the mechanism of hsCRP reduction seen with
tatins? Is it a direct anti-inflammatory effect of the statins,
r are other mechanisms possible? It also has been claimed
hat LDL reductions do not correlate with hsCRP reduc-
ion. These analyses are limited by not taking into account
he baseline hsCRP level, because a significant reduction is
ot expected in subjects without a baseline elevation. Ad-
itionally, a meta-analysis of various statin and statin-
zetimibe combination trials has found that the majority of
he CRP reduction is indeed related to the degree of LDL
owering (11). The data for ezetimibe are particularly
nteresting and relevant in this regard. As monotherapy
zetimibe does not reduce hsCRP levels, is only a modest
DL cholesterol-lowering drug (with an average LDL
eduction of 18% compared with 30% to 40% with starting toses of statins), and also leads to up-regulation of choles-
erol synthesis. In combination with statin therapy, how-
ver, the combined inhibition of intestinal and hepatic
holesterol pathways results in both a significant additive
DL cholesterol-lowering effect and a greater reduction
n hsCRP compared with statin monotherapy. The
zetimibe/statin data therefore suggest that the CRP
eductions seen with statin therapy may be related to the
eduction in liver cell cholesterol content rather than a
irect anti-inflammatory effect in the vasculature.
An important distinction needs to be made between
he predictive value of a risk factor in a population versus
hat in an individual (12). Beyond the issue of whether
sCRP is independently predictive beyond its metabolic
ilieu, there is significant overlap in hsCRP levels
etween those with and without events. Furthermore,
levated hsCRP levels are very prevalent. Indeed, in the
allas Heart Study, about one-half of black subjects
etween the ages of 30 and 65 years had CRP 3 mg/dl,
ith 63% of black women having levels above 3 mg/dl
13). Most positive studies on hsCRP have compared risk
ased not on hsCRP as a linear variable but on hsCRP
uartiles. Coupled with the biological linkage of hsCRP
nd other metabolic risk factors, it is therefore not
urprising that the sensitivity and specificity of the test
ay be insufficient to adequately predict risk in an
ndividual. In this regard, the receiver-operating charac-
eristic curve and its attendant C-statistic is an appropri-
te test for assessing the predictive value of a test in an
ndividual patient.
Given the previously detailed limitations for hsCRP, is
here any role for its routine measurement? As often is the
ase in medicine, the answer is: “it depends.” Atherosclerosis
oes not occur in an isolated state, and the inflammatory
ilieu can be identified by a multitude of signs. Indeed,
imilar to hsCRP, other markers of an inflammatory state,
uch as white blood cell count and particularly the neutro-
hil count, have been shown to predict coronary disease
14). High-sensitivity CRP is easy to measure and is a
elatively inexpensive test. Its strengths as well as its limi-
ations are a product of its relatively nonspecific nature—
levated in many and reflective of an underlying metabolic
ilieu. Some will therefore find this “global” test of inflam-
ation useful, particularly in educating the individual pa-
ient on the harmful effects of their metabolic perturbations.
thers will find it predictable and confirmatory.
How can we improve risk stratification given the limita-
ions of hsCRP and other biomarkers (including LDL
holesterol, which is, however, not only a biomarker but also
target for therapy)? The underlying disease is ultimately
therosclerosis, an anatomically defined entity. Imaging
odalities for atherosclerosis (15) may provide better pre-
ictive tools, and as these improve and become more
ffordable, they are likely to become the ideal partners to our
raditional risk assessment tools.
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